Top-quality stocks poised to benefit from long-term global growth
Three fund managers at Alliance Trust tell us what stocks they'd invest in.

Most economists and analysts were wrongfooted by macroeconomic developments in 2023, with many expecting a recession that didn’t materialise. This highlights the difficulty of basing an investment strategy on predictions of top-down factors such as GDP growth, interest rates or foreign exchange rates.
It is far better to focus on analysing the fortunes of individual companies. However volatile the macroeconomic environment, it should pay to look to the long-term fundamental strengths of businesses and build diversification into a portfolio through different ideas that pay off at different times.
Top air travel stock to buy
Andy Headley at Veritas highlights European giant Airbus (Paris: AIR), one of two key manufacturers of airframes, operating in a duopoly with US firm Boeing. Air travel remains robust and continues to grow, with an estimated 80% of the global population yet to set foot on a plane.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company’s most important product is its short-haul, single-aisle plane – the A320 – which competes with Boeing’s version, the 737. This new generation of planes is flying off the shelves on account of 20% greater fuel efficiency when compared with older planes, as airlines seek to reduce their carbon emissions.
We believe Airbus’s products are currently superior to Boeing’s. The group’s plan to increase production capacity by 50% should pave the way for strong growth and share-price performance over the medium- to long-term.
Top equipment rental to watch out for
Meanwhile, Jonathan Mills at Metropolis examines Ashtead (LSE: AHT), a large industrial and construction-equipment rental company, operating in the US, Canada and the UK. It buys a wide variety of equipment such as cranes, diggers, floor cleaners and even film-studio equipment, renting it to businesses for industrial and commercial purposes.
For individual firms, rentals usually reduce costs as equipment tends to be fairly specialised and therefore infrequently used, and storage and maintenance is expensive. What’s more, if equipment can be shared and more efficiently used, it’s friendlier for the environment.
An important part of the business model is that Ashtead is able to use its scale to purchase equipment in bulk at attractive prices and, therefore, rent it out on good margins. Ashtead is one of two leading companies within this sector, and with around 13% market share, there is plenty of room for growth.
A revolution in diabetes management
Finally, Sunil Thakor at Sands Capital highlights the medical device company Dexcom (Nasdaq: DXCM). It is a high-quality growth business and a leader in the field of continuous glucose monitoring. Diabetes affects an estimated one in eleven people around the world and is a potentially deadly disease.
Dexcom is one of the leading manufacturers of continuous glucose monitoring (CGM) devices, which are attached to the skin and track glucose to an app on your phone on an ongoing basis. These devices are revolutionising the management of diabetes, leading to fewer complications, greater longevity and a higher quality of life. Within this oligopolistic market, Dexcom offers a particularly strong product and associated software, and distributes them effectively through strong marketing and sales. As a result, Dexcom boasts a steadily growing market share, and we believe the company has strong and improving financials.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Both Jonathan and co-Founder & Portfolio Manager Simon Denison-Smith met whilst working as Strategy Consultants for Bain & Company. Jonathan brought this same analytical mindset and proactive spirit with him to Metropolis – co-founding the firm with Simon, and co-managing its global equity strategy since its launch in 2008.
-
Watch out for fake Steven Bartlett video – you could lose thousands
Scammers are trying to tap into the Trump tariffs chaos, but knowing what to look out for could save you thousands of pounds, says Kalpana Fitzpatrick
By Kalpana Fitzpatrick
-
Can Donald Trump fire Jay Powell – and what do his threats mean for investors?
Donald Trump has been vocal in his criticism of Jerome "Jay" Powell, chairman of the Federal Reserve. What do his threats to fire him mean for markets and investors?
By Katie Williams
-
LendInvest: a promising fintech firm going cheap
Opinion LendInvest has made some mistakes in the past, but it’s now primed for growth, says Rupert Hargreaves
By Rupert Hargreaves
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
Three top-notch Taiwanese companies cashing in on the advent of AI
Opinion Eric Chan, investment director and co-manager of the Aberdeen Asian Income Fund, highlights three potential Taiwanese winners in the technology industry
By Eric Chan